Chimeric, Mutated, Or Recombined Hybrid (e.g., Bifunctional, Bispecific, Rodent-human Chimeric, Single Chain, Rfv, Immunoglobulin Fusion Protein, Etc.) Patents (Class 530/387.3)
-
Patent number: 9884910Abstract: The invention relates to antibodies binding to the PDGF-C antigen and capable of inhibiting binding of PDGF-C to the PDGFR? receptor and of inhibiting PDGFR? activation by PDGF-C. Applications of such antibodies are also disclosed. These include treatment of cancer.Type: GrantFiled: April 24, 2013Date of Patent: February 6, 2018Assignee: ThromboGenics NVInventors: Claudia Fromond, Hoa Thu Ngo, Richard Zwaal, Sofie Notebaert
-
Patent number: 9879095Abstract: The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: February 21, 2013Date of Patent: January 30, 2018Assignee: HOFFMAN-LA ROCHE INC.Inventors: Ulrich Brinkmann, Alexander Haas, Silke Metz, Juergen Michael Schanzer
-
Patent number: 9862779Abstract: Herein is reported a method for producing a polypeptide comprising at least two polypeptide domains comprising the step of cultivating a cell comprising (a) a nucleic acid encoding a soluble S. aureus sortase A with a C-terminal endoplasmic reticulum retention signal, (b) a nucleic acid encoding a first polypeptide domain comprising at its C-terminus a sortase motif followed by an endoplasmic reticulum retention signal, and (c) a nucleic acid encoding a second polypeptide domain comprising at its N-terminus at least a diglycine, whereby the cell secretes the sortase A conjugate of the first polypeptide domain and the second polypeptide domain, thereby producing a polypeptide comprising at least two polypeptide domains.Type: GrantFiled: March 13, 2015Date of Patent: January 9, 2018Assignee: HOFFMANN-LA ROCHE INC.Inventors: Mariel Beck, Georg Tiefenthaler
-
Patent number: 9862776Abstract: The present invention relates to antibodies and antigen-binding fragments thereof that bind RYK, in particular human RYK and their use in regulating RYK-associated activities. Specifically there is provided an isolated monoclonal antibody or antigen-binding fragment or derivative thereof that specifically binds to the extracellular domain of human RYK, in particular, the antibody or antigen-binding fragment thereof, binds specifically to the WIF domain of human RYK. Preferably, the antibodies of the present invention modulate RYK-associated activity, which includes RYK mediated signal transduction activity and modulation of the interaction of Wnts with RYK and, preferably, modulate Wnt induced signaling. In particular, the antibodies inhibit the binding of Wnt5a and inhibit Wnt induced phosphorylation of Dishevelled (Dvl) 2 and/or Dvl3 proteins.Type: GrantFiled: April 2, 2014Date of Patent: January 9, 2018Assignee: Peter MacCallum Cancer InstituteInventors: Maria Luisa Macheda, Michael Maurice Halford, Steven Stacker, Clare Louise Parish, Edouard Collins Nice
-
Patent number: 9808507Abstract: An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody.Type: GrantFiled: August 25, 2015Date of Patent: November 7, 2017Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Seungja Oh, Kyung Ah Kim, Bo Gyou Kim, Seung Hyun Lee, Ji Min Lee
-
Patent number: 9777073Abstract: The present invention provides a bispecific antibody. The bispecific antibody provided by the present invention comprises a single-chain unit and a monovalent unit, wherein the single-chain unit has a specific binding capability against surface antigen CD3 of an immune cell; the monovalent unit has a specific binding capability against the surface antigen EpCAM of a tumor cell; the single-chain unit comprises a single-chain variable fragment ScFv fused with an Fc fragment; and the monovalent unit comprises a light chain and heavy chain pair. The present invention also provides a preparation method of the bispecific antibody and pharmaceutical use of these antibodies.Type: GrantFiled: July 20, 2015Date of Patent: October 3, 2017Assignee: Wuhan YZY Biopharma Co., Ltd.Inventors: Pengfei Zhou, Tao Wang, Lijuan Fang, Liu Hu, Yang Liu, Yu Zhang, Kesuo Fan
-
Patent number: 9771419Abstract: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.Type: GrantFiled: February 2, 2015Date of Patent: September 26, 2017Assignees: KYOWA HAKKO KIRIN CO., LIMITED, LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGYInventors: Steven W. Granger, Shinichiro Kato, Carl F. Ware
-
Patent number: 9765156Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.Type: GrantFiled: July 12, 2013Date of Patent: September 19, 2017Assignee: The Trustees of the University of PennsylvaniaInventors: Carl H. June, Yangbing Zhao, Xiaojun Liu
-
Patent number: 9751947Abstract: An anti-TrkA antibody is provided that comprises: a) a variable heavy chain comprising a sequence selected from any of BXhVH1, BXhVH2, BXhVH3, BXhVH4, BXhVH5, or HuVHWOv as shown in FIG. 1a; or from variants of any of said sequences and/or b) a variable light chain comprising a sequence selected from any of BXhVL1, BXhVL2, BXhVL3, BXhVL4, BXhVL5, BXhVL6, BXhVL7 or BXhVL8; as shown in FIG. 1b, or from variants of any of said sequences. TrkA-binding derivatives are also provided. Antibodies or derivatives of the present invention are useful in a number of therapies, including pain therapy.Type: GrantFiled: February 4, 2009Date of Patent: September 5, 2017Assignee: LAY LINE GENOMICS S.P.A.Inventors: Fabio Benigni, Daniele D'Ambrosio
-
Patent number: 9751939Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: September 16, 2010Date of Patent: September 5, 2017Assignee: Morphosys AGInventors: Stefan Steidl, Elisabeth Thomassen-Wolf
-
Patent number: 9745364Abstract: This invention provides an anti-idiotype antibody that binds to the antigen-binding region of an antibody encoded by antibody genes selected from the group consisting of Set I, Set II, Set III, Set IV, Set V, Set VIa, Set VIb, Set VIc, Set VId, Set VIe, Set VII, and Set VIII, hybridomas and methods of treatments using such.Type: GrantFiled: January 20, 2012Date of Patent: August 29, 2017Assignee: The Feinstein Institute for Medical ResearchInventors: Bradley T. Messmer, Nicholas Chiorazzi, Emilia Albesiano
-
Patent number: 9738723Abstract: The disclosure provides humanized anti-OX40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.Type: GrantFiled: October 7, 2015Date of Patent: August 22, 2017Assignee: MedImmune, LLCInventors: Scott A. Hammond, Michael Oberst, Qun Du, Melissa Damschroder
-
Patent number: 9737505Abstract: The compound (2R,2?R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate) possesses physicochemical properties suitable for pharmaceutical development and is capable of generating (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC) in quantities capable of depleting serum amyloid P component (SAP) efficiently following oral administration, making it useful in the treatment of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.Type: GrantFiled: October 28, 2015Date of Patent: August 22, 2017Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Alexis Denis, Olivier Mirguet, Jérôme Toum
-
Patent number: 9730983Abstract: A method for blocking, inhibiting and/or decreasing cluster of differentiation 14 (CD14) function, CD14-mediated cellular response and/or treating CD14-mediated pathological conditions is disclosed. The method comprises administering to a subject in need thereof a pharmaceutical composition comprising: (a) a therapeutically effective amount of a recombinant protein comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1, wherein the recombinant protein does not comprises a lectin-like domain 1 of a human thrombomodulin; and (b) a pharmaceutically acceptable vehicle, carrier, diluent, excipients, and/or salt.Type: GrantFiled: October 2, 2015Date of Patent: August 15, 2017Inventors: Chih-Yuan Ma, Guey-Yueh Shi, Hua-Lin Wu
-
Patent number: 9725506Abstract: The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with BLyS antagonists, either singly or in combination with other immune suppressive drugs.Type: GrantFiled: February 28, 2014Date of Patent: August 8, 2017Assignees: ZYMOGENETICS, INC., UNIVERSITY OF WASHINTONInventors: Stacey R. Dillon, Jane A. Gross, Keith B. Elkon
-
Patent number: 9708389Abstract: The invention relates to a method for preparing a homodimer protein mixture by using repulsive interaction of charges. The method comprises the step of replacing part of residues with the opposite-charged residues, so that different proteins or antibodies are unfavorable to forming heterodimers due to the repulsive interaction between like charges, while same proteins or antibodies are favorable to forming homodimers due to attractive interaction between opposite charges. The homodimer protein mixture obtained according to the method of the invention can simultaneously act on different epitopes of the same target, and simultaneously inhibit the effects of a plurality of antigens by binding to the antigens from different sources, thereby providing a new approach towards immunological diagnosis and treatment of tumors and other diseases.Type: GrantFiled: July 25, 2013Date of Patent: July 18, 2017Assignee: Suzhou Alphamab Co., Ltd.Inventors: Ting Xu, Tao Xu, Xiaoxiao Wang, Xinglu Sun, Ying Fan, Yan Zeng
-
Patent number: 9708403Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: March 23, 2015Date of Patent: July 18, 2017Assignees: NOVO NORDISK A/S, INNATE PHARMAInventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Petrus Johannes Louis Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Patent number: 9688756Abstract: Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment, that is, little or no binding activity at a physiologic pH. Also described are variant Fc-polypeptides that comprise these variant Fc-fragments. Further described are methods of making and identifying such Fc-fragments and methods for making and using such Fc-polypeptides.Type: GrantFiled: December 17, 2012Date of Patent: June 27, 2017Assignee: AMGEN INC.Inventors: Jeonghoon Sun, Seog Joon Han, Susie M Harris, Randal R Ketchem, Ji Lu, Mark L Michaels, Marc W Retter, Mei-Mei Tsai
-
Patent number: 9686970Abstract: Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.Type: GrantFiled: December 19, 2013Date of Patent: June 27, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Karolina A. Meagher, Andrew J. Murphy
-
Patent number: 9683052Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.Type: GrantFiled: March 23, 2012Date of Patent: June 20, 2017Assignee: Glenmark Pharmaceuticals S.A.Inventors: Stanislas Blein, Darko Skegro, Paul Wassmann
-
Patent number: 9683053Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.Type: GrantFiled: January 29, 2014Date of Patent: June 20, 2017Assignee: Glenmark Pharmaceuticals S.A.Inventors: Stanislas Blein, Darko Skegro, Paul Wassmann
-
Patent number: 9670269Abstract: The present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points between the H chains of two types of antibodies, wherein the difference is introduced by modifying the amino acids present on the surface of the antibody variable regions of two types of antibodies that constitute a bispecific antibody. Furthermore, the inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column by linking respective antigen binding sites (heavy chain variable regions) to the antibody constant regions having different isoelectric points, and then coexpressing these antibodies.Type: GrantFiled: March 30, 2007Date of Patent: June 6, 2017Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Tsunoda
-
Patent number: 9624309Abstract: This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases.Type: GrantFiled: August 16, 2008Date of Patent: April 18, 2017Assignee: BAYER INTELLECTUAL PROPERTY GmbHInventors: Bing Liu, David Light, Zhuozhi Wang, Douglas Schneider
-
Patent number: 9617348Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.Type: GrantFiled: April 10, 2013Date of Patent: April 11, 2017Assignee: Xencor, Inc.Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
-
Patent number: 9599619Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection, diagnosis and/or treatment of cancer, such as pancreatic cancer. The antibodies, such as PAM4 antibodies, bind to a PAM4 antigen that shows unique cell and tissue distributions compared with other known antibodies such as CA19.9, DUPAN2, SPAN1, Nd2, B72.3, and Lea and Le(y) antibodies that bind to the Lewis antigens.Type: GrantFiled: January 27, 2015Date of Patent: March 21, 2017Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang, David V. Gold
-
Patent number: 9586996Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.Type: GrantFiled: April 28, 2011Date of Patent: March 7, 2017Assignee: ESPERANCE PHARMACEUTICALS, INC.Inventors: Hector Alila, Carola Leuschner
-
Patent number: 9580461Abstract: The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography.Type: GrantFiled: July 27, 2011Date of Patent: February 28, 2017Assignee: MedImmune, LLCInventors: Thomas Linke, William K. Wang, Ambarish Shah, Hasige Sathish, Alan Hunter, Christopher Thompson
-
Patent number: 9574010Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: GrantFiled: November 2, 2012Date of Patent: February 21, 2017Assignee: Zymeworks Inc.Inventors: Thomas Spreter Von Kreudenstein, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Paula Irene Lario, David Kai Yuen Poon
-
Patent number: 9567390Abstract: This invention relates to a high affinity recombinant humanized antibody fragment (scFv) specific for hepatitis B surface antigen having unique inter/intra chain bonding interaction because of 28 altered amino acid residues from the original mouse (5S) antibody and its chimeric Fab form, wherein fine tuning of the vernier zone residue makes it closer to the human sequence without any structural constraints.Type: GrantFiled: December 2, 2008Date of Patent: February 14, 2017Assignees: Department of Biotechnology, All India Institute of Medical Sciences, International Center for Genetic and BiotechnologyInventors: Subrata Sinha, Ashutosh Tiwari, Navin Khanna, Subrat K. Acharya
-
Patent number: 9556274Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.Type: GrantFiled: February 27, 2013Date of Patent: January 31, 2017Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
-
Patent number: 9541547Abstract: The present invention provides novel antibodies. In particular, the present invention provides fusion antibodies comprising antibody heavy and light chain fusions. The present invention further provides multivalent antibodies comprising multiple fusion antibody chains. The present invention further provides methods of generating splice resistant antibody genes.Type: GrantFiled: March 9, 2010Date of Patent: January 10, 2017Assignee: CATALENT PHARMA SOLUTIONS, INC.Inventors: Gregory T. Bleck, Dona York, Ian Collins
-
Patent number: 9540451Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.Type: GrantFiled: April 10, 2013Date of Patent: January 10, 2017Assignee: Xencor, Inc.Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
-
Patent number: 9540438Abstract: The present disclosure provides aldehyde-tagged immunoglobulin (Ig) polypeptides that can be converted by a formylglycine-generating enzyme to produce a 2-formylglycine (FGly)-modified Ig polypeptide. An FGly-modified Ig polypeptide can be covalently and site-specifically bound to a moiety of interest to provide an Ig conjugate. The disclosure also encompasses methods of production of such aldehyde-tagged Ig polypeptides, FGly-modified Ig polypeptides, and Ig conjugates, as well as methods of use of same.Type: GrantFiled: January 13, 2012Date of Patent: January 10, 2017Assignee: Redwood Bioscience, Inc.Inventors: Robyn M. Barfield, Mark Alan Breidenbach, Gregory W. deHart, David Rabuka
-
Patent number: 9540618Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different.Type: GrantFiled: November 5, 2014Date of Patent: January 10, 2017Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Patent number: 9533055Abstract: Provided herein are compositions and related methods for delivering an IgG-decoy receptor to the CNS. The methods include systemic administration of a bifunctional decoy receptor-BBB receptor antibody fusion antibody comprising a receptor extracellular domain (ECD) covalently linked to an antibody to a receptor expressed on the surface of the blood-brain barrier (BBB receptor). In some embodiments, the compositions described herein are administered to treat a subject suffering from a CNS condition.Type: GrantFiled: March 18, 2010Date of Patent: January 3, 2017Assignee: ARMAGEN TECHNOLOGIES, INC.Inventors: William M. Pardridge, Ruben J. Boado
-
Patent number: 9534043Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: GrantFiled: February 17, 2010Date of Patent: January 3, 2017Assignee: Glaxo Group LimitedInventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Christopher Plummer, Oliver Schon
-
Patent number: 9518131Abstract: The present invention provides for a method for generating a metal ion binding protein, the method comprising a) integrating the amino acid sequence DDD into CDR1 of a light chain variable region of an antibody or fragment thereof; and b) combining the sequence of step a) with a heavy chain variable region of an antibody or fragment thereof; and c) isolating the protein. Also provided is the use of metal ion binding proteins generated by the method of the present invention for isolation and purification of proteins and for the reversible labeling of a target molecule. Also provided is a metal ion binding anti-CD8 protein.Type: GrantFiled: April 1, 2014Date of Patent: December 13, 2016Assignee: Miltenyi Biotech GmbHInventors: Holger Thie, Kristina Reck, Volker Nolle
-
Patent number: 9512228Abstract: The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.Type: GrantFiled: June 18, 2012Date of Patent: December 6, 2016Assignee: NOVO NORDISK A/SInventors: Kalle Soederstroem, Elisabeth Douglas Galsgaard
-
Patent number: 9512211Abstract: Antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: June 23, 2014Date of Patent: December 6, 2016Assignee: Alethia Biotherapeutics Inc.Inventors: Gilles Bernard Tremblay, Mario Filion, Traian Sulea
-
Patent number: 9499617Abstract: The present invention discloses humanized anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.Type: GrantFiled: December 19, 2013Date of Patent: November 22, 2016Assignee: Glaxo Group LimitedInventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
-
Patent number: 9487586Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.Type: GrantFiled: April 21, 2015Date of Patent: November 8, 2016Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE DE PARIS XI PARIS SUDInventors: Eric Rubinstein, Céline Greco, François Le Naour, Claude Boucheix
-
Patent number: 9481878Abstract: The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to toxin alone, antibody alone, unconjugated toxin plus antibody or even other types of toxin-antibody constructs. In a most preferred embodiment the construct comprises an anti-Trop-2 antibody conjugated to Rap, although other combinations of antibodies, antibody fragments and toxins may be used to form the subject immunotoxins. The immunotoxins are of use to treat a variety of diseases, such as cancer, autoimmune disease or immune dysfunction.Type: GrantFiled: September 4, 2013Date of Patent: November 1, 2016Assignees: Immunomedics, Inc., IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Patent number: 9481729Abstract: Disclosed are antibodies, or binding fragments thereof, that specifically bind to human HER2 and human IGF-IR. Also provided are nucleic acid molecules encoding the disclosed antibodies and binding fragments and vectors and host cells containing these nucleic acid molecules. The disclosure also provides methods of inhibiting cancer cell growth and metastasis in a mammal using the antibodies described herein, as well as compositions containing the antibodies, nucleic acid molecules encoding the antibodies, and host cells and vectors comprising the nucleic acid molecules. The disclosure also features the use of the polypeptides to detect the presence of HER2 and IGF-IR in a mammal, and epitopes that can be used as cancer vaccine immunogens.Type: GrantFiled: September 11, 2014Date of Patent: November 1, 2016Assignee: The University of Hong KongInventor: Mei-Yun Zhang
-
Patent number: 9468689Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.Type: GrantFiled: December 18, 2013Date of Patent: October 18, 2016Assignee: Immunomedics, Inc.Inventors: Li Zeng, Rohini Mitra, Edmund A. Rossi, Hans J. Hansen, David M. Goldenberg
-
Patent number: 9453078Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: September 26, 2013Date of Patent: September 27, 2016Assignee: CYTOMX THERAPEUTICS, INC.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
-
Patent number: 9446123Abstract: The present invention concerns multimeric complexes based on antibody fusion proteins comprising an AD moiety attached to the C-terminal end of each antibody light chain. The complexes further comprise effector moities attached to DDD moieties. Two copies of the DDD moiety form a dimer that binds to the AD moiety. The complexes may be trimers, pentamers, hexamers or other multimers. The effector moieties may be selected from a second antibody or antigen-binding fragment thereof, a cytokine, an interferon, a toxin, an antigen, a xenoantigen, a hapten, a protamine, a hormone, an enzyme, a ligand-binding protein, a pro-apoptotic agent and an anti-angiogenic agent. Surprisingly, attachment of the AD moiety to the C-terminal end of the antibody light chain results in improved pharmacokinetics and in vivo stability and efficacy, compared to homologous complexes wherein the AD moiety is attached to the antibody heavy chain.Type: GrantFiled: May 24, 2013Date of Patent: September 20, 2016Assignee: IBC Pharmaceuticals, Inc.Inventors: Edmund A. Rossi, Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 9445581Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising the disclosed antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in the disclosed methods.Type: GrantFiled: March 28, 2012Date of Patent: September 20, 2016Assignee: Kymab LimitedInventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Dominik Spensberger, Hui Liu, Jasper Clube
-
Patent number: 9428548Abstract: The present invention provides methods for purifying a polypeptide comprising a CH2/CH3 region, comprising binding the polypeptide to Protein A and eluting with a pH gradient starting at a low pH.Type: GrantFiled: September 1, 2010Date of Patent: August 30, 2016Assignee: Genentech, Inc.Inventors: Arick Brown, Christopher J. Dowd, Asha Nandini Radhamohan
-
Patent number: 9428580Abstract: The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae.Type: GrantFiled: September 15, 2011Date of Patent: August 30, 2016Assignee: ARGEN-X B.V.Inventors: Torsten Dreier, Christophe Frederic Jerome Blanchetot, Johannes Joseph Wilhelmus De Haard
-
Patent number: 9416175Abstract: The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1.Type: GrantFiled: March 18, 2014Date of Patent: August 16, 2016Assignee: CureTech Ltd.Inventors: Rinat Rotem-Yehudar, Michael Schickler